Preferred Treatment of Type 1.5 Diabetes

Clinical Trial ID NCT00194896

PubWeight™ 0.84‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00194896

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 102.56
2 Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002 7.00
3 Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1998 6.13
4 Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994 5.28
5 Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 1993 2.63
6 Banting lecture 1990. Beta-cells in type II diabetes mellitus. Diabetes 1991 2.45
7 Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993 2.15
8 Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 1997 1.76
9 Transfer of insulin-dependent diabetes between HLA-identical siblings by bone marrow transplantation. Lancet 1993 1.68
10 Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990 1.51
11 Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 1993 1.44
12 Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview. Diabetologia 1992 1.38
13 Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994 1.36
14 Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis. Diabetes 1986 1.26
15 The pathogenesis and prevention of diabetes in adults. Genes, autoimmunity, and demography. Diabetes Care 1995 1.18
16 Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987 1.18
17 Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia 1996 1.17
18 Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes-prone animals. Diabetologia 1985 1.08
19 Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type. J Clin Invest 1993 1.07
20 Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus. Diabetes 1992 1.06
21 Cellular immune responses to human islet proteins in antibody-positive type 2 diabetic patients. Diabetes 1999 1.02
22 Organ-specific autoimmunity and HLA-DR antigens as markers for beta-cell destruction in patients with type II diabetes. Diabetes 1988 1.00
23 Small doses of subcutaneous insulin as a strategy for preventing slowly progressive beta-cell failure in islet cell antibody-positive patients with clinical features of NIDDM. Diabetes 1996 0.97
24 Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify type 1(1/2) diabetes in patients presenting with type 2 diabetes. Metabolism 2001 0.92
25 Residual beta-cell function and HLA-A24 in IDDM. Markers of glycemic control and subsequent development of diabetic retinopathy. Diabetes 1995 0.89
26 Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (type 1) diabetes mellitus. Ann N Y Acad Sci 2002 0.89
27 The functional state of the beta cell modulates IL-1 and TNF-induced cytotoxicity. Lymphokine Cytokine Res 1993 0.85
28 Functional state of the beta cell affects expression of both forms of glutamic acid decarboxylase. Pancreas 1994 0.84
29 Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients. Clin Exp Immunol 2013 0.84
30 Time course of islet cell antibodies and beta-cell function in non-insulin-dependent stage of type I diabetes. Diabetes 1987 0.84
31 Maleness as risk factor for slowly progressive IDDM. Diabetes Care 1989 0.83
32 Relationships among islet cell antibodies, residual beta-cell function, and metabolic control in patients with insulin-dependent diabetes mellitus of long duration: use of a sensitive C-peptide radioimmunoassay. Metabolism 1990 0.82
33 Correlation of islet cell antibodies and HLA-DR phenotypes with diabetes mellitus in adults. Diabetologia 1984 0.82
34 Subtype of insulin-dependent diabetes mellitus (IDDM) in Japan: slowly progressive IDDM--the clinical characteristics and pathogenesis of the syndrome. Diabetes Res Clin Pract 1994 0.79
35 Predictive value of insulin autoantibodies for further progression of beta cell dysfunction in non-insulin-dependent diabetics. Diabetes Res 1988 0.77
Next 100